相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study
Marlies E. J. Reinders et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients
S. E. de Boer et al.
BMC NEPHROLOGY (2021)
Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR
Cynthia S. M. Kramer et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Alemtuzumab: Rare serious adverse events of a high-efficacy drug
Hans-Peter Hartung et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
Marieke van der Zwan et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Acquired haemophilia A after alemtuzumab therapy
Marieke van der Zwan et al.
HAEMOPHILIA (2020)
Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
Marieke van der Zwan et al.
FRONTIERS IN IMMUNOLOGY (2020)
Presence of intragraft B cells during acute renal allograft rejection is accompanied by changes in peripheral blood B cell subsets
S. Heidt et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
Krista Barclay et al.
FRONTIERS IN NEUROLOGY (2019)
Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use
Jean Kwun et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft
Floris C. Loeff et al.
TRANSPLANT IMMUNOLOGY (2019)
Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study
Alexandre Loupy et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
Marieke van der Zwan et al.
TRANSPLANTATION DIRECT (2019)
Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection
Denis Viglietti et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
M. Haas et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology
Candice Roufosse et al.
TRANSPLANTATION (2018)
What is the impact of human leukocyte antigen mismatching on graft survival and mortality in renal transplantation? A meta-analysis of 23 cohort studies involving 486,608 recipients
Xinmiao Shi et al.
BMC NEPHROLOGY (2018)
Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
Marieke van der Zwan et al.
CLINICAL PHARMACOKINETICS (2018)
Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients A systematic review and meta-analysis of randomized controlled trials
Jianming Zheng et al.
MEDICINE (2017)
Risk prediction models for graft failure in kidney transplantation: a systematic review
Remi Kabore et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
Jonna R. Bank et al.
TRANSPLANTATION DIRECT (2017)
Beneficial Immune Effects of Myeloid-Related Proteins in Kidney Transplant Rejection
N. V. Rekers et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Mechanisms and risk assessment of steroid resistance in acute kidney transplant rejection
Niels V. Rekers et al.
TRANSPLANT IMMUNOLOGY (2016)
The Risk of Transplant Failure With HLA Mismatch in First Adult Kidney Allografts From Deceased Donors
Robert C. Williams et al.
TRANSPLANTATION (2016)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
Karel G. M. Moons et al.
ANNALS OF INTERNAL MEDICINE (2015)
Follicular T helper cells and humoral reactivity in kidney transplant patients
G. N. de Graav et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Treatment of Steroid-Resistant Acute Renal Allograft Rejection With Alemtuzumab
M. W. F. van den Hoogen et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Immune status following alemtuzumab treatment in human CD52 transgenic mice
Michael J. Turner et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis
Sambasiva P. Rao et al.
PLOS ONE (2012)
Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients
Rachael A. Clark et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Alemtuzumab Induction in Renal Transplantation
Michael J. Hanaway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Impacts of CD38+ B Cells on Acute Cellular Rejection With CD20+ B Cells in Renal Allograft
Hyeon Seok Hwang et al.
TRANSPLANTATION (2010)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
Yanping Hu et al.
IMMUNOLOGY (2009)
Acute Rejection and Chronic Nephropathy: A Systematic Review of the Literature
Olivia Wu et al.
TRANSPLANTATION (2009)
Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody
Anton Y. Peleg et al.
CLINICAL INFECTIOUS DISEASES (2007)
Expression of surfactant protein-C, S100A8, S100A9, and B cell markers in renal allografts: Investigation of the prognostic value
M Eikmans et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Association of CD20+infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts
BE Hippen et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Influence of kidney function to the impact of acute rejection on long-term kidney transplant survival
PC Nett et al.
TRANSPLANT INTERNATIONAL (2005)
Expression of CD52 on plasma cells in plasma cell proliferative disorders
S Kumar et al.
BLOOD (2003)
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H)
AD Kirk et al.
TRANSPLANTATION (2003)
Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling
M Sarwal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Early versus late acute rejection episodes in renal transplantation
YWJ Sijpkens et al.
TRANSPLANTATION (2003)
分享论文
